Today, there are few commercial preparations of AAT purified from human plasma that are used to treat patients with congenital AAT deficiency, and these preparations are also being tested for their therapeutic potential outside of AAT deficiency (18). The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.